Hemolysis induced by 6-N-hydroxylaminopurine riboside, an adenosine analogue.
6-N-Hydroxylaminopurine riboside (HAPR) was studied in man because of its therapeutic activity in several transplanted animal neoplasms. It was not cross-resistant to other antimetabolites useful in the treatment of human neoplasia. HAPR produced marked hemolytic anemia at doses far below those that might have produced any cytotoxic or therapeutic effect. There was evidence of hemolysis at total doses as low as 0.5 mg/kg given intravenously. For man, HAPR is one of the most active hemolytic drugs.
D000241:Adenosine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D000328:Adult; D001663:Bilirubin / Q000032:analysis; D001772:Blood Cell Count; D001943:Breast Neoplasms / Q000188:drug therapy; D004176:Dipyridamole / Q000627:therapeutic use; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D006898:Hydroxylamines / Q000008:administration & dosage / Q000032:analysis / Q000097:blood* / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy; D011687:Purines / Q000008:administration & dosage; D012004:Rectal Neoplasms / Q000188:drug therapy; D012156:Reticulocytes; D013997:Time Factors
D006454:Hemoglobins; D006898:Hydroxylamines; D011687:Purines; D004176:Dipyridamole; D000241:Adenosine; D001663:Bilirubin